1 August 2014 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
5 February 2013 in British Journal of Cancer
Background: Methods: Results: Conclusion:
4 May 2011 in Obstetrics and Gynecology International
LCLambert Naudin Ten Cate
ESElzbieta M. van der Steen-Banasik
Elzbieta M. van der Steen-Banasik
+4
Objective. The aim of this study is to look at possible differences in outcome between serosa and adnexal involvement stage IIIA endometrial carcinoma. Methods. 67 patients with stage IIIA endometrial carcinoma were included, 46 with adnexal involvement and 21 with serosa. A central histopathological review was performed. Results. The 7-year locoregional failure rate was (LRFR) 2.2% for adnexal involvement and 16.0% for involvement of the serosa (𝑃=.0522). The 7-year distant metastasis-free survival was 72.7% for adnexal involvement and 58.7% for serosa (𝑃=.3994). The 7-year disease-specific survival (DSS) was 71.8% for patients with adnexal involvement and 75.4% for patients with serosa. Conclusion. Endometrial carcinoma stage IIIA with involvement of the adnexa or serosa showed to have a comparable disease-specific survival. Locoregional control was worse for serosa involvement compared to adnexa.
28 February 2010 in European Journal of Surgical Oncology
1 April 2012 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
23 September 2015 in Acta Oncologica
Background. The aim of this study is to analyze the impact of first degree relative (FDR) of young breast cancer patients. Methods. Data were used from our prospective population-based cohort study which started in 1983. The family history (FH) was registered with regard to FDR: the presence or absence of invasive breast cancer in none vs. one or more FDRs at any age. Results. A total of 1109 women, ≤50 years with 1128 breast conserving treatments was seen. The incidence of FDR was 17.0% for one FDR and 3.2% ≥2 FDR. The three groups, none, 1 or ≥2 FDR, were comparable. The local failure rate is comparable for all three groups. Women with a positive FH and metachronous bilateral breast cancer (MBBC) showed a lower local failure (HR 0.2; 95% CI 0.05–0.8). A positive FH was an independent predictor for a better disease-specific survival (HR 0.6; 95% CI 0.4–0.9). Conclusion. A positive FH, based on FDR implies a better prognosis in relation to survival for young women treated with BCT. In contrast to no FH for FDR, MBBC in women with a positive FH was not associated with an increased risk of local recurrence.